Insulin Degludec Insulin Aspart Brand Name– RYZODEG
What is Insulin Degludec Insulin Aspart
Insulin degludec Insulin aspart is the combination of a long-acting, basal insulin analog along with a rapid-acting insulin analog.
In adults with type 1 and 2 diabetes mellitus (DM) who had inadequate glycemic control at clinical trial entry, treatment with insulin degludec; insulin aspart provided A1C reductions equivalent to reductions achieved with other, previously approved long-acting or pre-mixed insulin.
The most common adverse reactions are hypoglycemia, allergic reactions, injection site reactions, pitting at the injection site (lipodystrophy), itching, rash, edema, and weight gain.
Severe, life-threatening allergic reactions, including anaphylaxis, may occur.
In the treatment of type 1 diabetes mellitus (DM), insulin therapy may be initiated with a basal-bolus regimen and then further individualized to achieve treatment goals.
In the treatment of type 2 DM, insulin is generally reserved for patients who continue to have an A1C above target despite dual/triple therapy with metformin and other antidiabetic agents.
In patients who need the greater glucose-lowering effect of an injectable medication, GLP-1 receptor agonists (GLP-1 RA) are the preferred choice to insulin. Evidence from trials comparing GLP-1 RAs and insulin (basal, premixed, or basal-bolus) shows similar or even better efficacy in A1C reduction; GLP-1 RAs have a lower risk of hypoglycemia and are associated with reductions in body weight compared to weight gain with insulin. In patients who cannot tolerate a GLP-1 RA, or who fail to meet glycemic targets with dual/triple therapy, insulin therapy with basal insulin should be initiated and titrated to target. If A1C remains above target, prandial insulin or pre-mixed insulin, such as insulin degludec; insulin aspart mixture, should be added. Consider an initial injectable combination (i.e., GLP-1 RA plus basal insulin or prandial/basal insulin) if A1C is greater than 10% and 2% above target.
Consider the early introduction of insulin if there is evidence of ongoing catabolism, if symptoms of hyperglycemia are present, or when A1C levels (greater than 10%) or blood glucose levels (300 mg/dL or more) are very high.
In patients who are starting on insulin therapy and are taking a thiazolidinedione or sulfonylurea, discontinue or reduce the dose of the oral medication.
Indications
- type 1 diabetes mellitus
- type 2 diabetes mellitus
Side Effects
- anaphylactoid reactions
- angioedema
- antibody formation
- bronchospasm
- cutaneous amyloidosis
- headache
- hyperinsulinemia
- hypertension
- hypoglycemia
- hypokalemia
- hypotension
- infection
- influenza
- injection site reaction
- insulin resistance
- insulin shock
- lipodystrophy
- peripheral edema
- pharyngitis
- rash
- Somogyi effect
- urticaria
- weight gain
- wheezing
Monitoring Parameters
- blood glucose
- glycosylated hemoglobin A1c (HbA1c)
Contraindications
- breast-feeding
- coma
- continuous subcutaneous insulin infusion (CSII) administration
- diabetic ketoacidosis
- diarrhea
- fever
- geriatric
- hepatic disease
- hyperosmolar hyperglycemic state (HHS)
- hypoglycemia
- hypokalemia
- infection
- intravenous administration
- neonates
- pregnancy
- renal failure
- renal impairment
- surgery
- thyroid disease
- tobacco smoking
- trauma
- visual impairment
- vomiting
Interactions
No information is available regarding drug interactions associated with Insulin Degludec Insulin Aspart
